Article
NTRK fusion analysis reveals enrichment in Middle Eastern BRAF wild-type PTC
1 Feb 2021
Abstract excerpt
Objective: Fusions involving neurotrophic tyrosine receptor kinase (NTRK) are known oncogenic drivers in a broad range of tumor types. It recently gained attention as a predictor of targeted therapy since selective NTRK inhibitors are now approved in the US and Europe for patients with solid tumors harboring gene fusions. However, estimation of NTRK gene fusion/alteration frequency and its clinicopathological...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
